Phaseline

Targets › SELENOW

SELENOW (Selenoprotein W): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 2; Cardiovascular, Psychiatry; next expected readout Apr 2027.

Plays a role as a glutathione (GSH)-dependent antioxidant. May be involved in a redox-related process. (UniProt, P63302)

Open in Phaseline: the race on SELENOW, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Skane University HospitalSelenium (Bio-SelenoPrecise)
Selenium supplementation; trace element cofactor for selenoproteins involved in antioxidan
SELENOP, SELENOWPhase 3Heart FailureMar 2030
First Affiliated Hospital of Chongqing Medical Universityselenium yeast supplementation
selenium cofactor for selenoprotein synthesis
SELENOP, SELENOK, SELENOW, SELENOFPhase 2Depression - Major Depressive DisorderApr 2027

Conditions

Heart Failure (1) Depression - Major Depressive Disorder (1)

Modalities

small molecule (1)

Companies

Skane University Hospital (1) First Affiliated Hospital of Chongqing Medical University (1)

Related targets

SELENOP (2) SELENOK (1) SELENOF (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.